Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Post by DryBoneson Aug 19, 2018 12:39pm
165 Views
Post# 28483783

Baloney?

Baloney?The mindless pumpers keep tryiing to assert that  bashers and mself are challenging the efficacy of PLI's deep drug pipeline.  I have never done so as Barcy seems to imply. Nor can I recall anyone else doing so.

The real issue is not the pipeline.  The real issue is whether management can deliver operating cash from somewhere and whether it will be hard money (diluting investment) or paid up equity (partnership).

Everything now depends upon this.  More clinical trial results at this stage won't help this process.  The companies negotiating with PLI have enough clinical information to make a decision.  Further results are not likely change the efficacy picture. (what's better than 100%).  I am skeptical about management delivering any where near to their plan due to their track record.  

I do think partnership is possible right now.
Bullboard Posts